Today in kidney research
Brief for 2026-08-10 · generated 2026-08-10T16:46:58.786Z
Coverage gap: 24 rss/page sources waiting on Forager (FORAGER_URL not set)
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
This is a new trial that is just starting. It will test a drug called AP306 in adults on dialysis who have too much phosphate in their blood. High phosphate is common in dialysis and can harm the heart and bones. The study checks if the drug is safe and lowers phosphate, and there are no results yet.
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
This trial is starting. It tests whether pushing blood pressure down harder, using water pills (diuretics), works better than usual care. The people have moderate to severe kidney disease and high blood pressure that is not controlled. Lower blood pressure protects kidneys over time, but this study has no results yet.
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This trial is starting. It tests a pill called empagliflozin against a placebo (a dummy pill) in children ages 2 to 17 with kidney disease. This drug already helps adults with kidney disease. The study will see if it is safe and helps children, and there are no results yet.
Assessment of the Impact of Repeated Ischemic Preconditioning Episodes on Hemodynamic and Metabolic Parameters in Patients at Various Stages of Chronic Kidney Disease
This trial is starting. It briefly cuts and restores blood flow to a limb on purpose, over and over, to see if this protects blood vessels and the heart in people with kidney disease. It will track blood pressure, heart rate, and signs of inflammation. This idea is unproven in kidney patients, and there are no results yet.
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This is a large Phase 3 trial that is starting. It tests a drug called elecoglipron against a placebo in adults with type 2 diabetes and reduced kidney function. Everyone also takes dapagliflozin, a standard kidney-protecting drug. The study checks safety and how well it works, and there are no results yet.
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
This study is starting. It looks at a treatment called physiologic insulin resensitization in people who have both kidney disease and type 2 diabetes. This approach is not widely proven. There are no results yet.
Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients
This is a real-world study that is starting. It will follow about 90 adults with kidney disease (not on dialysis) who have low blood counts (anemia), grouped by their inflammation levels. They take a pill called enarodustat, and the study watches safety and whether anemia improves. There are no results yet.
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This large trial is starting and will run about 5 years. It tests a pill called orforglipron against a placebo in people with heart disease and/or kidney disease. It will measure heart attacks, strokes, and related outcomes. There are no results yet.
Niaoduqing Granules in Older Adults With Impaired Kidney Function
This real-world study is starting. It will follow about 300 adults over 60 with stage 3 to 5 kidney disease who are not on dialysis. It looks at whether an herbal medicine, Niaoduqing Granules, slows kidney decline and helps nutrition and strength. There are no results yet, and real-world studies cannot prove cause.
Urinary Dickkopf-3 reflects renal and vascular damage in diabetic kidney disease: A cross-sectional study.
This study measured a urine marker called Dickkopf-3 (DKK3) in people with diabetic kidney disease. Higher levels went along with more kidney and blood-vessel damage. This is a one-time snapshot, so it shows a link, not proof of cause.
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.
This is a meta-analysis, which pools many studies together, on GLP-1 drugs (like semaglutide) in people with end-stage kidney disease. Pooling studies gives stronger evidence than any single one. It reports how well these drugs work and how safe they are in this fragile group.
Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes.
This is an expert review on tailoring both drug and non-drug care for people whose kidney disease is caused by diabetes. It pulls together current advice for matching treatment to the person. It is guidance, not new study results.
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
This is a planned pooled analysis of three large trials (SELECT, FLOW, and SOUL) covering thousands of people. It looks at how semaglutide affects the kidneys. Combining big trials gives strong evidence. It reports whether semaglutide protects kidney function.
Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease
This trial tested dapagliflozin, an SGLT2 pill, in children with kidney disease. It reported that the drug protected kidney function and lowered protein in the urine (albuminuria). Trials in children are small, so the effect still needs larger studies to confirm. It points the same way as the strong adult evidence.
Prevention of new-onset chronic kidney disease with renin–angiotensin system blockers in type 2 diabetes with preserved kidney function
This study looked at whether blood-pressure drugs that block the renin-angiotensin system can stop kidney disease from starting in people with type 2 diabetes who still have normal kidney function. It reports a protective link. Read it as an association, not proof, unless it was a randomized trial; it points to prevention as possible.
The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.
This is a review of how an unhealthy balance of gut bacteria may play a part in metabolic kidney disease. A review gathers other work; it is not a new experiment. It points to the gut as a possible target but proves nothing on its own.
Association Between Dietary Magnesium Intake and All-Cause Mortality in Patients with Chronic Kidney Disease: Insights from NHANES 1999-2018.
This study used a large US health survey to link diet magnesium with the risk of dying in people with kidney disease. People who ate more magnesium tended to live longer. This is an observational link, not proof, and diet surveys can be inexact.
Regulatory Frameworks and Technical Bottlenecks for Clinical Translation of the Bioartificial Kidney.
This is an expert review of the rules and technical hurdles to bringing a bioartificial kidney (a lab-built kidney-replacing device) to patients. It maps what still blocks the path to the clinic. It is opinion and background, not a test of the device.
Proteomic Identification of Pig Xenoantigens for Clinical Xenotransplantation.
This lab study found proteins on pig cells that the human immune system would attack. Knowing these targets could help make pig organs safer for transplant into people. This work was done in the lab, not in patients yet.
Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older: A Population-Based Cohort Study
This large community study checked how well a standard kidney-screening approach (KDIGO) worked in adults aged 75 and older. It found the screening helped predict who was at risk of harm. This is an observational cohort, so it shows patterns, not proof of cause.